TTK Healthcare Share Price
1110.15+0.00 (+5.48%)
-1.59% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
GRASIMNSE
3MINDIANSE
DCMSHRIRAMNSE
HNDFDSNSE
BALMLAWRIENSE
TTKHLTCARENSE
KOTICNSE
EMPINDNSE
GILLANDERSNSE
ASPINWALLNSE
TTK Healthcare Share Price
1110.15+0.00 (+5.48%)
-1.59% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| 5% | 12% | 6% | 7% |
| 11% | 7% | -53% | -20% |
| 3% | 11% | -5% | -2% |
| 9% | 7% | 7% | 6% |
Peer Comparison
Symbol
GRASIM
3MINDIA
DCMSHRIRAM
HNDFDS
BALMLAWRIE
TTKHLTCARE
KOTIC
EMPIND
GILLANDERS
ASPINWALL
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 3,101 | ₹211300 Cr | 43.07 | -3.44 | 190.34 | ₹4966 Cr |
| 28,180 | ₹31543 Cr | 57.89 | 140.62 | 542.87 | ₹522 Cr |
| 881.6 | ₹13870 Cr | 10.05 | 6.72 | 122.53 | ₹853 Cr |
| 550.5 | ₹6668 Cr | 40.3 | 3.71 | 21.9 | ₹149 Cr |
| 163.98 | ₹2818 Cr | 9.33 | 4.65 | 22.64 | ₹277 Cr |
| 1,086.6 | ₹1483 Cr | 5.36 | 157.8 | 201.84 | ₹66 Cr |
| 114.15 | ₹1251 Cr | — | -2.47 | -8.73 | -₹72 Cr |
| 1,024.85 | ₹603 Cr | 9.82 | 29.49 | 129.91 | ₹52 Cr |
| 97.25 | ₹204 Cr | 12.31 | 6.28 | 12.67 | ₹9 Cr |
| 230 | ₹184 Cr | 11.12 | 4.6 | 28.77 | ₹13 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | Dec 2018 | Sep 2018 | Jun 2018 | Mar 2018 | Dec 2017 | Sep 2017 | Jun 2017 | Mar 2017 | Dec 2016 | Sep 2016 | Jun 2016 | Mar 2016 | Dec 2015 | Sep 2015 | Jun 2015 | Mar 2015 | Dec 2014 | Sep 2014 | Jun 2014 | Mar 2014 | Dec 2013 | Sep 2013 | Jun 2013 | Mar 2013 | Dec 2012 | Sep 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹233 Cr | ₹258 Cr | ₹218 Cr | ₹209 Cr | ₹204 Cr | ₹226 Cr | ₹190 Cr | ₹205 Cr | ₹198 Cr | ₹208 Cr | ₹181 Cr | ₹184 Cr | ₹186 Cr | ₹202 Cr | ₹180 Cr | ₹183 Cr | ₹170 Cr | ₹193 Cr | ₹159 Cr | ₹159 Cr | ₹206 Cr | ₹131 Cr | ₹181 Cr | ₹179 Cr | ₹160 Cr | ₹116 Cr | ₹137 Cr | ₹166 Cr | ₹165 Cr | ₹179 Cr | ₹140 Cr | ₹149 Cr | ₹166 Cr | ₹173 Cr | ₹145 Cr | ₹146 Cr | ₹156 Cr | ₹130 Cr | ₹117 Cr | ₹123 Cr | ₹136 Cr | ₹153 Cr | ₹120 Cr | ₹131 Cr | ₹130 Cr | ₹139 Cr | ₹112 Cr | ₹121 Cr | ₹120 Cr | ₹130 Cr | ₹101 Cr | ₹106 Cr | ₹101 Cr | ₹109 Cr | ₹86 Cr | ₹92 Cr | ₹96 Cr |
| ₹19 Cr | ₹17 Cr | ₹18 Cr | ₹17 Cr | ₹19 Cr | ₹18 Cr | ₹19 Cr | ₹18 Cr | ₹18 Cr | ₹17 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹15 Cr | ₹16 Cr | ₹12 Cr | ₹11 Cr | ₹10 Cr | ₹5 Cr | ₹4 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr |
| ₹252 Cr | ₹274 Cr | ₹236 Cr | ₹227 Cr | ₹223 Cr | ₹244 Cr | ₹209 Cr | ₹223 Cr | ₹216 Cr | ₹225 Cr | ₹197 Cr | ₹200 Cr | ₹202 Cr | ₹217 Cr | ₹196 Cr | ₹194 Cr | ₹181 Cr | ₹202 Cr | ₹164 Cr | ₹163 Cr | ₹209 Cr | ₹135 Cr | ₹185 Cr | ₹182 Cr | ₹162 Cr | ₹118 Cr | ₹139 Cr | ₹168 Cr | ₹167 Cr | ₹180 Cr | ₹142 Cr | ₹151 Cr | ₹168 Cr | ₹175 Cr | ₹147 Cr | ₹148 Cr | ₹157 Cr | ₹132 Cr | ₹118 Cr | ₹125 Cr | ₹137 Cr | ₹154 Cr | ₹121 Cr | ₹132 Cr | ₹131 Cr | ₹140 Cr | ₹114 Cr | ₹122 Cr | ₹122 Cr | ₹131 Cr | ₹102 Cr | ₹107 Cr | ₹102 Cr | ₹111 Cr | ₹88 Cr | ₹95 Cr | ₹97 Cr |
| ₹232 Cr | ₹245 Cr | ₹209 Cr | ₹204 Cr | ₹200 Cr | ₹226 Cr | ₹181 Cr | ₹199 Cr | ₹192 Cr | ₹203 Cr | ₹172 Cr | ₹182 Cr | ₹180 Cr | ₹195 Cr | ₹168 Cr | ₹177 Cr | ₹169 Cr | ₹192 Cr | ₹157 Cr | ₹153 Cr | ₹194 Cr | ₹128 Cr | ₹170 Cr | ₹171 Cr | ₹154 Cr | ₹121 Cr | ₹137 Cr | ₹161 Cr | ₹160 Cr | ₹174 Cr | ₹134 Cr | ₹142 Cr | ₹156 Cr | ₹161 Cr | ₹133 Cr | ₹131 Cr | ₹142 Cr | ₹144 Cr | ₹111 Cr | ₹118 Cr | ₹128 Cr | ₹144 Cr | ₹112 Cr | ₹120 Cr | ₹123 Cr | ₹132 Cr | ₹105 Cr | ₹114 Cr | ₹115 Cr | ₹125 Cr | ₹96 Cr | ₹101 Cr | ₹96 Cr | ₹107 Cr | ₹83 Cr | ₹89 Cr | ₹90 Cr |
| ₹22 Cr | ₹32 Cr | ₹29 Cr | ₹25 Cr | ₹24 Cr | ₹21 Cr | ₹31 Cr | ₹26 Cr | ₹26 Cr | ₹24 Cr | ₹28 Cr | ₹21 Cr | ₹26 Cr | ₹25 Cr | ₹31 Cr | ₹20 Cr | ₹15 Cr | ₹14 Cr | ₹10 Cr | ₹13 Cr | ₹19 Cr | ₹10 Cr | ₹18 Cr | ₹14 Cr | ₹11 Cr | ₹1 Cr | ₹5 Cr | ₹11 Cr | ₹10 Cr | ₹10 Cr | ₹12 Cr | ₹12 Cr | ₹15 Cr | ₹18 Cr | ₹18 Cr | ₹21 Cr | ₹19 Cr | -₹8 Cr | ₹11 Cr | ₹9 Cr | ₹11 Cr | ₹13 Cr | ₹12 Cr | ₹14 Cr | ₹10 Cr | ₹10 Cr | ₹11 Cr | ₹9 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹7 Cr |
| ₹59 L | ₹53 L | ₹64 L | ₹68 L | ₹84 L | ₹77 L | ₹91 L | ₹82 L | ₹74 L | ₹86 L | ₹93 L | ₹24 L | ₹73 L | ₹86 L | ₹95 L | ₹78 L | ₹80 L | ₹3 Cr | ₹97 L | ₹1 Cr | ₹55 L | ₹46 L | ₹66 L | ₹35 L | ₹59 L | ₹63 L | ₹93 L | ₹91 L | ₹75 L | ₹68 L | ₹69 L | ₹70 L | ₹94 L | ₹1 Cr | ₹96 L | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹60 L | ₹70 L | ₹80 L | ₹1 Cr | ₹1 Cr | ₹71 L | ₹72 L | ₹76 L | ₹96 L | ₹94 L | ₹76 L | ₹98 L | ₹78 L | ₹69 L | ₹78 L | ₹74 L | ₹62 L | ₹64 L | ₹72 L |
| ₹268 Cr | ₹29 Cr | ₹30 Cr | ₹14 Cr | ₹21 Cr | ₹18 Cr | ₹22 Cr | ₹23 Cr | ₹23 Cr | ₹41 Cr | ₹24 Cr | ₹18 Cr | ₹22 Cr | ₹21 Cr | ₹27 Cr | ₹16 Cr | ₹11 Cr | ₹8 Cr | ₹6 Cr | ₹8 Cr | ₹17 Cr | ₹6 Cr | ₹14 Cr | ₹11 Cr | ₹15 Cr | -₹3 Cr | ₹94 L | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹8 Cr | ₹11 Cr | ₹13 Cr | ₹14 Cr | ₹16 Cr | ₹14 Cr | -₹13 Cr | ₹7 Cr | ₹6 Cr | ₹7 Cr | ₹9 Cr | ₹8 Cr | ₹12 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹6 Cr | ₹6 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹3 Cr | ₹4 Cr | ₹5 Cr | ₹6 Cr |
| ₹223 Cr | ₹21 Cr | ₹22 Cr | ₹11 Cr | ₹20 Cr | ₹13 Cr | ₹16 Cr | ₹17 Cr | ₹17 Cr | ₹32 Cr | ₹18 Cr | ₹13 Cr | ₹16 Cr | ₹16 Cr | ₹17 Cr | ₹12 Cr | ₹10 Cr | ₹601 Cr | ₹11 Cr | ₹12 Cr | ₹13 Cr | ₹6 Cr | ₹10 Cr | ₹8 Cr | ₹31 Cr | -₹2 Cr | ₹42 L | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr | ₹5 Cr | ₹7 Cr | ₹8 Cr | ₹8 Cr | ₹12 Cr | ₹11 Cr | -₹13 Cr | ₹5 Cr | ₹4 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹4 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Revaluation reserve
Shareholder's Funds
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Less Impairment of Assets
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr |
| ₹1101 Cr | ₹1051 Cr | ₹987 Cr | ₹939 Cr | ₹316 Cr | ₹281 Cr | ₹235 Cr | ₹237 Cr | ₹219 Cr | ₹150 Cr | ₹128 Cr | ₹111 Cr | ₹99 Cr | ₹90 Cr | ₹80 Cr | ₹68 Cr | ₹57 Cr | ₹54 Cr | ₹49 Cr |
| ₹1096 Cr | ₹1047 Cr | ₹982 Cr | ₹935 Cr | ₹311 Cr | ₹276 Cr | ₹230 Cr | ₹233 Cr | ₹214 Cr | ₹145 Cr | ₹124 Cr | ₹106 Cr | ₹95 Cr | ₹86 Cr | ₹75 Cr | ₹63 Cr | ₹52 Cr | ₹49 Cr | ₹44 Cr |
| ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr |
| ₹1115 Cr | ₹1065 Cr | ₹1001 Cr | ₹953 Cr | ₹330 Cr | ₹295 Cr | ₹249 Cr | ₹251 Cr | ₹233 Cr | ₹157 Cr | ₹136 Cr | ₹118 Cr | ₹107 Cr | ₹98 Cr | ₹88 Cr | ₹76 Cr | ₹65 Cr | ₹62 Cr | ₹57 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹33 L | ₹66 L | ₹87 L | ₹1 Cr | ₹16 Cr | ₹16 Cr | ₹58 L | ₹47 L | ₹62 L | ₹6 Cr | ₹15 Cr | ₹13 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹8 Cr | ₹6 L | ₹6 L |
| -₹6 Cr | -₹6 Cr | -₹5 Cr | -₹4 Cr | -₹7 Cr | -₹6 Cr | -₹4 Cr | -₹5 Cr | -₹5 Cr | ₹2 Cr | ₹5 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹96 L | -₹1 Cr |
| ₹2 Cr | ₹2 Cr | ₹80 L | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹0 | ₹0 | ₹0 | ₹10 Cr | ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹0 | ₹0 | ₹0 |
| ₹6 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹5 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹6 Cr | ₹4 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹2 Cr | -₹74 L | -₹2 Cr | ₹2 Cr | ₹1 Cr | ₹4 Cr | ₹7 Cr | ₹2 Cr | ₹2 Cr | ₹8 Cr | ₹16 Cr | ₹28 Cr | ₹27 Cr | ₹11 Cr | ₹10 Cr | ₹9 Cr | ₹16 Cr | ₹16 Cr | ₹12 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹91 Cr | ₹107 Cr | ₹102 Cr | ₹111 Cr | ₹103 Cr | ₹98 Cr | ₹87 Cr | ₹73 Cr | ₹86 Cr | ₹67 Cr | ₹33 Cr | ₹30 Cr | ₹30 Cr | ₹29 Cr | ₹36 Cr | ₹32 Cr | ₹54 Cr | ₹46 Cr | ₹38 Cr |
| ₹61 Cr | ₹56 Cr | ₹53 Cr | ₹53 Cr | ₹68 Cr | ₹67 Cr | ₹54 Cr | ₹52 Cr | ₹31 Cr | ₹30 Cr | ₹90 Cr | ₹72 Cr | ₹59 Cr | ₹46 Cr | ₹37 Cr | ₹36 Cr | ₹20 L | ₹14 L | ₹9 L |
| ₹22 Cr | ₹22 Cr | ₹21 Cr | ₹26 Cr | ₹20 Cr | ₹18 Cr | ₹28 Cr | ₹28 Cr | ₹46 Cr | ₹22 Cr | ₹22 Cr | ₹22 Cr | ₹13 Cr | ₹22 Cr | ₹18 Cr | ₹12 Cr | ₹0 | ₹0 | ₹0 |
| ₹32 Cr | ₹27 Cr | ₹24 Cr | ₹21 Cr | ₹7 Cr | ₹6 Cr | ₹2 Cr | ₹5 Cr | ₹3 Cr | ₹77 L | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹27 Cr | ₹20 Cr | ₹14 Cr | ₹11 Cr |
| ₹206 Cr | ₹211 Cr | ₹202 Cr | ₹211 Cr | ₹199 Cr | ₹189 Cr | ₹172 Cr | ₹157 Cr | ₹168 Cr | ₹120 Cr | ₹150 Cr | ₹129 Cr | ₹106 Cr | ₹100 Cr | ₹94 Cr | ₹108 Cr | ₹73 Cr | ₹60 Cr | ₹49 Cr |
| ₹1323 Cr | ₹1275 Cr | ₹1201 Cr | ₹1166 Cr | ₹551 Cr | ₹488 Cr | ₹427 Cr | ₹411 Cr | ₹403 Cr | ₹285 Cr | ₹303 Cr | ₹275 Cr | ₹240 Cr | ₹209 Cr | ₹192 Cr | ₹193 Cr | ₹154 Cr | ₹138 Cr | ₹118 Cr |
| ₹17 Cr | ₹21 Cr | ₹14 Cr | ₹27 Cr | ₹26 Cr | ₹14 Cr | ₹25 Cr | ₹22 Cr | ₹25 Cr | ₹18 Cr | ₹17 Cr | ₹19 Cr | ₹17 Cr | ₹17 Cr | ₹18 Cr | ₹20 Cr | ₹17 Cr | ₹5 Cr | ₹10 Cr |
| ₹22 Cr | ₹22 Cr | ₹21 Cr | ₹26 Cr | ₹20 Cr | ₹18 Cr | ₹28 Cr | ₹29 Cr | ₹47 Cr | ₹23 Cr | ₹38 Cr | ₹42 Cr | ₹32 Cr | ₹22 Cr | ₹18 Cr | ₹13 Cr | ₹14 Cr | ₹15 Cr | ₹13 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹182 Cr | ₹183 Cr | ₹178 Cr | ₹164 Cr | ₹165 Cr | ₹159 Cr | ₹149 Cr | ₹144 Cr | ₹141 Cr | ₹111 Cr | ₹146 Cr | ₹86 Cr | ₹83 Cr | ₹70 Cr | ₹58 Cr | ₹56 Cr | ₹46 Cr | ₹41 Cr | ₹37 Cr |
| ₹109 Cr | ₹103 Cr | ₹103 Cr | ₹93 Cr | ₹85 Cr | ₹73 Cr | ₹60 Cr | ₹46 Cr | ₹31 Cr | ₹12 Cr | ₹40 Cr | ₹34 Cr | ₹29 Cr | ₹27 Cr | ₹25 Cr | ₹23 Cr | ₹22 Cr | ₹20 Cr | ₹19 Cr |
| ₹0 | ₹0 | ₹12 L | ₹0 | ₹0 | ₹0 | ₹13 L | ₹92 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹73 Cr | ₹81 Cr | ₹75 Cr | ₹71 Cr | ₹80 Cr | ₹85 Cr | ₹89 Cr | ₹98 Cr | ₹110 Cr | ₹99 Cr | ₹106 Cr | ₹52 Cr | ₹54 Cr | ₹43 Cr | ₹33 Cr | ₹33 Cr | ₹24 Cr | ₹21 Cr | ₹18 Cr |
| ₹1 Cr | ₹8 L | ₹79 L | ₹3 Cr | ₹19 L | ₹45 L | ₹9 Cr | ₹2 Cr | ₹79 L | ₹25 L | ₹85 L | ₹46 Cr | ₹2 Cr | ₹31 L | ₹6 Cr | ₹5 Cr | ₹6 Cr | ₹0 | ₹3 L |
| ₹9 Cr | ₹11 Cr | ₹13 Cr | ₹13 Cr | ₹15 Cr | ₹13 Cr | ₹9 Cr | ₹13 Cr | ₹9 Cr | ₹9 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹6 Cr | ₹8 Cr | ₹8 Cr | ₹3 Cr |
| ₹9 Cr | ₹11 Cr | ₹13 Cr | ₹13 Cr | ₹15 Cr | ₹13 Cr | ₹9 Cr | ₹13 Cr | ₹9 Cr | ₹9 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹6 Cr | ₹8 Cr | ₹8 Cr | ₹3 Cr |
| ₹11 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹7 Cr | ₹14 Cr | ₹23 Cr | ₹27 Cr | ₹28 Cr | ₹10 Cr | ₹12 Cr | ₹12 Cr | ₹21 Cr | ₹11 Cr | ₹7 Cr | ₹1 Cr | ₹0 | ₹0 | ₹0 |
| ₹11 Cr | ₹67 Cr | ₹23 Cr | ₹1 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹105 Cr | ₹171 Cr | ₹124 Cr | ₹100 Cr | ₹102 Cr | ₹113 Cr | ₹129 Cr | ₹139 Cr | ₹147 Cr | ₹118 Cr | ₹119 Cr | ₹109 Cr | ₹77 Cr | ₹55 Cr | ₹46 Cr | ₹45 Cr | ₹38 Cr | ₹29 Cr | ₹21 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹10 Cr | ₹13 L | ₹13 L | ₹77 L | ₹7 Cr | ₹84 L | ₹0 | ₹0 | ₹0 |
| ₹109 Cr | ₹109 Cr | ₹97 Cr | ₹85 Cr | ₹79 Cr | ₹70 Cr | ₹72 Cr | ₹55 Cr | ₹53 Cr | ₹44 Cr | ₹41 Cr | ₹37 Cr | ₹34 Cr | ₹27 Cr | ₹33 Cr | ₹27 Cr | ₹23 Cr | ₹20 Cr | ₹16 Cr |
| ₹111 Cr | ₹91 Cr | ₹86 Cr | ₹92 Cr | ₹54 Cr | ₹60 Cr | ₹77 Cr | ₹80 Cr | ₹55 Cr | ₹34 Cr | ₹47 Cr | ₹44 Cr | ₹38 Cr | ₹35 Cr | ₹37 Cr | ₹32 Cr | ₹22 Cr | ₹22 Cr | ₹18 Cr |
| ₹633 Cr | ₹786 Cr | ₹775 Cr | ₹847 Cr | ₹274 Cr | ₹228 Cr | ₹132 Cr | ₹126 Cr | ₹136 Cr | ₹82 Cr | ₹77 Cr | ₹77 Cr | ₹84 Cr | ₹84 Cr | ₹62 Cr | ₹61 Cr | ₹49 Cr | ₹50 Cr | ₹50 Cr |
| ₹40 Cr | ₹34 Cr | ₹31 Cr | ₹27 Cr | ₹8 Cr | ₹7 Cr | ₹6 Cr | ₹5 Cr | ₹4 Cr | ₹2 Cr | ₹75 L | ₹75 L | ₹75 L | ₹79 L | ₹79 L | ₹73 L | ₹0 | ₹0 | ₹0 |
| ₹325 Cr | ₹84 Cr | ₹88 Cr | ₹15 Cr | ₹11 Cr | ₹11 Cr | ₹12 Cr | ₹6 Cr | ₹8 Cr | ₹4 Cr | ₹7 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹7 Cr | ₹26 Cr | ₹21 Cr | ₹17 Cr | ₹12 Cr |
| ₹1218 Cr | ₹1104 Cr | ₹1077 Cr | ₹1066 Cr | ₹425 Cr | ₹375 Cr | ₹298 Cr | ₹272 Cr | ₹256 Cr | ₹167 Cr | ₹184 Cr | ₹166 Cr | ₹163 Cr | ₹154 Cr | ₹146 Cr | ₹148 Cr | ₹116 Cr | ₹109 Cr | ₹97 Cr |
| ₹1012 Cr | ₹893 Cr | ₹876 Cr | ₹855 Cr | ₹226 Cr | ₹186 Cr | ₹127 Cr | ₹115 Cr | ₹88 Cr | ₹47 Cr | ₹34 Cr | ₹37 Cr | ₹57 Cr | ₹54 Cr | ₹52 Cr | ₹40 Cr | ₹42 Cr | ₹49 Cr | ₹48 Cr |
| ₹1323 Cr | ₹1275 Cr | ₹1201 Cr | ₹1166 Cr | ₹551 Cr | ₹488 Cr | ₹427 Cr | ₹411 Cr | ₹403 Cr | ₹285 Cr | ₹303 Cr | ₹275 Cr | ₹240 Cr | ₹209 Cr | ₹192 Cr | ₹193 Cr | ₹154 Cr | ₹138 Cr | ₹118 Cr |
| ₹786 | ₹751 | ₹705 | ₹672 | ₹230 | ₹205 | ₹173 | ₹175 | ₹162 | ₹197 | ₹170 | ₹147 | ₹132 | ₹121 | ₹107 | ₹92 | ₹77 | ₹71 | ₹65 |
| ₹786 | ₹751 | ₹705 | ₹672 | ₹230 | ₹205 | ₹173 | ₹175 | ₹162 | ₹197 | ₹170 | ₹147 | ₹132 | ₹121 | ₹107 | ₹92 | ₹77 | ₹71 | ₹65 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹83 Cr | ₹108 Cr | ₹84 Cr | ₹838 Cr | ₹58 Cr | ₹37 Cr | ₹19 Cr | ₹39 Cr | ₹30 Cr | ₹29 Cr | ₹36 Cr | ₹26 Cr | ₹20 Cr | ₹22 Cr | ₹24 Cr | ₹22 Cr | ₹16 Cr | ₹13 Cr | ₹22 Cr |
| -₹58 Cr | -₹81 Cr | -₹49 Cr | -₹803 Cr | ₹24 L | -₹3 Cr | ₹7 Cr | ₹10 Cr | ₹13 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹6 Cr | ₹4 Cr | ₹5 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | -₹11 Cr |
| -₹33 Cr | -₹3 Cr | -₹15 Cr | -₹44 Cr | -₹4 Cr | ₹42 Cr | ₹4 Cr | -₹19 Cr | -₹7 Cr | -₹13 Cr | ₹4 Cr | ₹15 Cr | -₹9 Cr | ₹6 Cr | -₹8 Cr | ₹8 Cr | ₹5 Cr | -₹3 L | -₹26 L |
| -₹8 Cr | ₹24 Cr | ₹20 Cr | -₹9 Cr | ₹54 Cr | ₹76 Cr | ₹31 Cr | ₹31 Cr | ₹36 Cr | ₹26 Cr | ₹50 Cr | ₹52 Cr | ₹17 Cr | ₹32 Cr | ₹21 Cr | ₹33 Cr | ₹24 Cr | ₹17 Cr | ₹11 Cr |
| -₹21 Cr | -₹4 Cr | -₹5 Cr | -₹25 Cr | ₹45 Cr | ₹96 Cr | ₹20 Cr | ₹17 Cr | ₹25 Cr | ₹18 Cr | ₹37 Cr | ₹39 Cr | ₹13 Cr | ₹24 Cr | ₹6 Cr | ₹25 Cr | ₹19 Cr | ₹13 Cr | ₹8 Cr |
| ₹52 Cr | ₹20 Cr | ₹28 Cr | ₹32 Cr | -₹30 Cr | -₹77 Cr | -₹13 Cr | ₹10 Cr | -₹23 Cr | ₹5 Cr | -₹27 Cr | -₹49 Cr | -₹15 Cr | -₹52 L | -₹4 Cr | -₹7 Cr | -₹11 Cr | -₹9 Cr | ₹20 Cr |
| -₹18 Cr | -₹18 Cr | -₹22 Cr | -₹12 Cr | -₹10 Cr | -₹17 Cr | -₹10 Cr | -₹31 Cr | -₹7 Cr | -₹23 Cr | -₹11 Cr | ₹3 Cr | ₹2 Cr | -₹2 Cr | -₹94 L | -₹7 Cr | -₹9 Cr | -₹3 Cr | -₹5 Cr |
| ₹13 Cr | -₹2 Cr | ₹2 Cr | -₹6 Cr | ₹5 Cr | ₹2 Cr | -₹4 Cr | -₹4 Cr | -₹4 Cr | ₹13 L | -₹16 L | -₹7 Cr | ₹25 L | ₹22 Cr | ₹100 L | ₹11 Cr | -₹91 L | ₹40 L | ₹24 Cr |
| ₹9 Cr | ₹11 Cr | ₹9 Cr | ₹15 Cr | ₹10 Cr | ₹8 Cr | ₹11 Cr | ₹15 Cr | ₹19 Cr | ₹19 Cr | ₹77 Cr | ₹84 Cr | ₹83 Cr | ₹62 Cr | ₹61 Cr | ₹49 Cr | ₹50 Cr | ₹50 Cr | ₹26 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹34 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹22 Cr | ₹9 Cr | ₹11 Cr | ₹9 Cr | ₹15 Cr | ₹10 Cr | ₹8 Cr | ₹11 Cr | ₹15 Cr | ₹19 Cr | ₹77 Cr | ₹77 Cr | ₹84 Cr | ₹83 Cr | ₹62 Cr | ₹61 Cr | ₹49 Cr | ₹50 Cr | ₹50 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
TTK Healthcare Share Price
1110.15+0.00 (+5.48%)
-1.59% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 5
Bearish signals: 4 out of 9 oscillators
RSI
64.21Buy
STOCH %K
88.50Sell
MACD Level(12,26)
12.59Buy
Ultimate Oscillator
61.13Buy
Aroon Oscillator
-68.00Sell
BOP
0.50Buy
CCI
165.54Sell
Williams %R
-11.50Sell
Momentum
195.90Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 9
Bearish signals: 0 out of 9 moving averages
EMA 9
1020.64Buy
SMA 9
999.26Buy
EMA 21
995.37Buy
SMA 21
972.96Buy
EMA 50
1005.13Buy
SMA 50
1012.57Buy
EMA 200
1014.73Buy
SMA 200
961.22Buy
WMA 20
985.85Buy
Pivot
Pivot
Classic
Resistance 5
1339.53
Resistance 4
1266.23
Resistance 3
1192.93
Resistance 2
1119.63
Resistance 1
1086.07
Pivot
1046.33
Support 1
1012.77
Support 2
973.03
Support 3
899.73
Support 4
826.43
Support 5
753.13
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
TTK Healthcare Share Price
1110.15+0.00 (+5.48%)
-1.59% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 74.56% | 74.56% | 74.56% | 74.56% | 74.56% | 74.56% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.11% | 2.19% | 1.11% | 1.08% | 1.18% | 1.14% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.04% |
| 25.33% | 23.25% | 24.33% | 24.36% | 24.26% | 24.26% |
Bulk & block deals
Name
Uno Metals Ltd
Uno Metals Ltd
Clubmillionaire Financial Services Private Limited
Abakkus Asset Manager Llp
Abakkus Diversified Alpha Fund
Mcap India Fund Limited
Abakkus Asset Manager Llp
Mcap India Fund Limited
Mcap India Fund Limited
Abakkus Diversified Alpha Fund
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 17 Mar 2025 | Sell | 8.60 Cr | ₹1,124.24 | 76.50 K | Bulk | 0.54139 | NSE |
| 31 Jul 2024 | Purchase | 15.03 Cr | ₹1,541.59 | 97.51 K | Bulk | 0.690099 | NSE |
| 31 Jul 2024 | Sell | 13.46 Cr | ₹1,541.13 | 87.33 K | Bulk | 0.618069 | NSE |
| 24 Mar 2023 | Purchase | 12.01 Cr | ₹911.08 | 1.32 L | Bulk | 0.932662 | BSE |
| 24 Mar 2023 | Purchase | 10.50 Cr | ₹910 | 1.15 L | Block | 0.816579 | BSE |
| 24 Mar 2023 | Sell | 11.87 Cr | ₹910 | 1.30 L | Block | 0.923462 | BSE |
| 24 Mar 2023 | Purchase | 11.87 Cr | ₹910 | 1.30 L | Block | 0.923462 | BSE |
| 24 Mar 2023 | Sell | 10.50 Cr | ₹910 | 1.15 L | Block | 0.816579 | BSE |
| 24 Mar 2023 | Sell | 22.37 Cr | ₹910 | 2.46 L | Bulk | 1.740041 | BSE |
| 24 Mar 2023 | Purchase | 10.50 Cr | ₹910 | 1.15 L | Bulk | 0.816579 | BSE |
Insider trading & SAST
Client name
Tiruvallur Lakshman
Mukund Thattai
Sarayu Thattai
Tiruvallur Lakshman
Sarayu Thattai
Mukund Thattai
Late Thiruvallur Thattai Venkatesh
Late Thiruvallur Thattai Jagannathan
Thiruvallur Thatai Lakshman
Mukund Thiruvallur Thattai
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28 Jan 2026 | Other | Acquisition | 1.79 | — | 0 | — | 2.53 L | 26 Dec 2025 | - | — | SAST | 10(6) | — |
| 28 Jan 2026 | Other | Acquisition | 1.79 | — | 0 | — | 2.53 L | 26 Dec 2025 | - | — | SAST | 10(6) | — |
| 28 Jan 2026 | Other | Acquisition | 1.89 | — | 0 | — | 2.67 L | 26 Dec 2025 | - | — | SAST | 10(6) | — |
| 28 Jan 2026 | Promoter | Acquisition | 1.79 | 1.89 | 0 | — | 2.53 L | 26 Dec 2025 | Transmission | 2,67,195 | SAST | 29(2) | — |
| 28 Jan 2026 | Promoter | Acquisition | 1.89 | 1.89 | 0 | — | 2.67 L | 26 Dec 2025 | Transmission | 2,67,100 | SAST | 29(2) | — |
| 28 Jan 2026 | Promoter | Acquisition | 1.79 | 1.89 | 0 | — | 2.53 L | 26 Dec 2025 | Transmission | 2,67,195 | SAST | 29(2) | — |
| 30 Dec 2025 | Promoter Group | Disposal | 0.099078 | 0 | 0 | — | 14 K | 26 Dec 2025 | Others | 0 | Insider Trading | — | Equity Shares |
| 30 Dec 2025 | Promoter | Disposal | 5.373545 | 0 | 0 | — | 7.59 L | 26 Dec 2025 | Others | 0 | Insider Trading | — | Equity Shares |
| 30 Dec 2025 | Promoter Group | Acquisition | 1.791179 | 1.89 | 0 | — | 2.53 L | 26 Dec 2025 | Others | 2,67,195 | Insider Trading | — | Equity Shares |
| 30 Dec 2025 | Promoter & Director | Acquisition | 1.791179 | 1.89 | 0 | — | 2.53 L | 26 Dec 2025 | Others | 2,67,195 | Insider Trading | — | Equity Shares |
TTK Healthcare Share Price
1110.15+0.00 (+5.48%)
-1.59% past 1 Year
TTK Healthcare Limited is committed to providing customers with innovative “value for money” products and solutions for improving their quality of life. The company has four Strategic Business Units i.e.
Corporate Actions
Date
Type
Details
Company details
TTK Healthcare Share Price
1110.15+0.00 (+5.48%)
-1.59% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
TTK Healthcare Share Price
1110.15+0.00 (+5.48%)
-1.59% past 1 Year
News
1 of 20
Stock NewsTTKHLTCARE16 Nov 2026
NULL
TTK Healthcare informs about closure of trading window
Stock NewsTTKHLTCARE16 Nov 2026
NULL
TTK Healthcare Reports Q2 Revenue Growth To Rs 233 Crores
ResultTTKHLTCARE30 Oct 2026
TTK Healthcare reported Q2 revenue of Rs 233 crores, compared with Rs 200 crores in the corresponding quarter a year earlier, representing 16.5 percent YoY growth. EBITDA, PAT, operating margin, net margin, QoQ performance, analyst expectations, management commentary, and market reaction were not provided and are therefore not included.
TTK Healthcare Q2 Profit Declines Amid Rs 250 Crore Exceptional Item
ResultTTKHLTCARE30 Oct 2026
TTK Healthcare reported Q2 standalone profit before tax of Rs 19.70 crores, down from Rs 21.30 crores in the corresponding quarter a year earlier. Revenue, EBITDA, PAT, margins, and sequential comparisons were not provided in the available update and are therefore not included.
The company recorded an exceptional item of Rs 250.00 crores during the quarter. The lower year-on-year profit before tax, together with the substantial exceptional item, indicates a mixed quarterly outcome. No management guidance, analyst consensus comparison, or market reaction was provided.
TTK Healthcare Q2 EBITDA Declines, Margin Contracts Year On Year
ResultTTKHLTCARE30 Oct 2026
TTK Healthcare reported Q2 EBITDA of Rs 3.70 crores, down from Rs 5.33 crores in the year-ago quarter, representing a year-on-year decline of approximately 30.6%. EBITDA margin contracted to 1.6% from 2.62% a year earlier, a reduction of 102 basis points. Revenue and PAT figures, quarter-on-quarter comparisons, management commentary, analyst expectations, and market reaction were not provided in the available update.
The reported decline in EBITDA and operating margin indicates weaker quarterly operating profitability compared with the corresponding period last year. TTK Healthcare is listed on the NSE under the symbol TTKHLTCARE.
TTK Healthcare Q1 EBITDA surges with sharp improvement in margin performance
ResultTTKHLTCARE6 Aug 2026
TTK Healthcare has reported a strong improvement in operating performance for the latest reported quarter, with EBITDA rising to Rs 14.70 crores from Rs 2.70 crores on a year-on-year basis. This represents a multi-fold increase in absolute operating earnings, indicating better cost management, operating leverage, or a richer product mix across its business segments. The sharp uptick in EBITDA highlights a meaningful turnaround in the company’s profitability at the operating level compared to the same period last year.
Alongside the surge in EBITDA, the company’s Q1 EBITDA margin expanded significantly to 5.7% from 1.2% year-on-year. This margin expansion of over 450 basis points suggests that the company has been able to enhance operational efficiency and reduce the drag from fixed and variable costs relative to revenues. A move from low single-digit to mid-single-digit margins is particularly relevant for market participants tracking the sustainability of earnings and the scalability of the business model. While detailed revenue and PAT figures are not provided in the available context, the substantial improvement in EBITDA and margin metrics alone points to a stronger underlying operating profile.
No information is available in the given context on quarterly revenue trends, PAT, management commentary, guidance, or comparisons versus street expectations. There is also no verifiable data here on the immediate stock price reaction or trading volumes on NSE/BSE for TTK Healthcare following the result disclosure. In this setting, market participants will likely focus on whether this improvement in EBITDA and margins can be sustained across subsequent quarters, and how it translates into net profitability and cash flows. For now, the reported numbers indicate a notable operating performance improvement for TTK Healthcare in Q1 on a year-on-year basis.
Ttk Healthcare posts higher Q1 net profit and revenue on yearly basis
ResultTTKHLTCARE6 Aug 2026
TTK Healthcare reported Q1 net profit of Rs 21.30 crores versus Rs 13.00 crores a year earlier, reflecting a year on year increase of about 63.8 percent.
Revenue for the quarter rose to Rs 260.00 crores from Rs 230.00 crores in the same period last year, up about 13.0 percent year on year.
No EBITDA, margin, or quarterly comparison figures were provided in the available context, so only the reported top line and bottom line numbers are included. The update is a routine quarterly results disclosure for TTK Healthcare under the equity earnings category.
TTK Healthcare to sell Eva, Good Home brands to Wipro Enterprises for Rs 256 crores
Stock NewsTTKHLTCARE23 Jul 2026
TTK Healthcare has announced a corporate transaction involving the sale of its Eva and Good Home brands to Wipro Enterprises for a total consideration of Rs 256 crores. The deal represents a significant brand monetisation move for the company, transferring ownership of these consumer-focused product lines to a larger diversified conglomerate. Eva and Good Home operate in personal care and home care segments, respectively, and their sale may reshape TTK Healthcare's portfolio composition, with a potential shift in strategic focus toward remaining businesses and core competencies.
For TTK Healthcare, the inflow of Rs 256 crores can strengthen the balance sheet, providing liquidity that may be used for debt reduction, reinvestment into higher-margin segments, or funding future expansion initiatives. While specific utilisation plans have not been disclosed, such a transaction typically offers scope to improve capital allocation efficiency and support long-term growth. The brand transfer to Wipro Enterprises suggests that Eva and Good Home will gain access to broader distribution, marketing capability, and possible product innovation under a larger corporate umbrella, which could influence competitive dynamics in the personal and home care categories.
From an earnings perspective, TTK Healthcare may see a change in revenue mix post-transaction, as income from these brands will be replaced over time by returns generated from redeployed capital or other operating segments. The impact on market share will depend on how TTK Healthcare leverages the proceeds to reinforce its remaining portfolio and how Wipro Enterprises scales Eva and Good Home. Although immediate stock price reaction and further financial details such as profitability of the divested brands are not available, the deal size of Rs 256 crores indicates a material but company-specific event rather than a broad market or index-moving development.
TTK Healthcare sees 2.07 percent Q1 stake disclosed by investor Abakkus
Stock NewsTTKHLTCARE20 Jul 2026
TTK Healthcare has come into focus in the equity markets after investor Sunil Singhania, through his Abakkus platform, reported a 2.07 percent stake in the company in the Q1 shareholding pattern. This disclosure indicates that Abakkus has accumulated a meaningful minority position, large enough to be reported in quarterly filings, underscoring growing institutional interest in the stock. The context around Abakkus and TTK Healthcare is important, as Sunil Singhania-led Abakkus Asset Manager LLP and Abakkus Diversified Alpha Fund have previously transacted in TTK Healthcare via open market and block deals, signalling a considered investment approach rather than a purely trading-oriented position.
A stake of 2.07 percent, while not altering control dynamics at TTK Healthcare, can be material for market perception. TTK Healthcare continues to be largely promoter-driven, with the promoter group retaining a dominant majority stake, and institutional plus public shareholders forming the balance ownership. In this backdrop, Abakkus emerging as a reported shareholder adds to the roster of recognised institutional investors and can be interpreted by market participants as a vote of confidence in the company’s business prospects, governance standards, and long-term earnings potential. Historically, TTK Healthcare has exhibited steady financial performance in its healthcare-related operations, and the entry or buildup of a well-known fund manager’s stake often draws incremental attention from other investors and market analysts.
From a market impact standpoint, such a stake disclosure is typically viewed as stock-specific news rather than a broader sector or index event. It may influence trading interest and valuation expectations in TTK Healthcare, particularly among investors who track institutional flows and specialty fund positions. However, there is no indication from the available context of any concurrent corporate action such as buyback, rights issue, large capex announcement, or regulatory order linked directly to this stake. The development primarily reflects portfolio positioning by Abakkus and could lead to closer monitoring of TTK Healthcare’s subsequent quarterly results, capital allocation, and industry positioning as investors assess whether further accumulation or strategic engagement by institutional shareholders might occur over time.
TTK Prestige clarifies no encumbrance, no Rs 250 crore pharma stake deal
Stock NewsTTKHLTCARE17 Jun 2026
TTK Prestige has issued a clarification regarding recent market speculation around its equity holdings and an alleged large pharma sector investment. The company has stated that it has not created any encumbrance on its holding of 1,440 equity shares, addressing concerns that there might have been a pledge, lien, or any other form of charge on these securities. This clarification reduces uncertainty for investors who may have been worried about potential promoter or corporate-level leverage linked to these specific shares, and indicates that there is no additional balance sheet risk arising from such an encumbrance.
Additionally, TTK Prestige has clarified that it has not acquired any stake worth Rs 250 crores in any pharmaceutical company, contradicting earlier interpretations or rumours that suggested a substantial diversification or acquisition in the pharma space. By confirming that no such Rs 250 crore pharma stake purchase has taken place, the company signals that there is no immediate large capital outlay or associated integration risk on this front. This also implies that there is no change, for now, in its core strategic focus or capital allocation plan on account of a major pharma transaction. Overall, the announcement serves primarily as a corrective disclosure to remove misinformation rather than to announce a new corporate action such as M&A, capex, or stake sale. The update is expected to provide clarity to the market, limit speculation-driven volatility, and help investors assess TTK Prestige on the basis of its existing business fundamentals without factoring in an unsubstantiated pharma investment or additional encumbrance-related risk.
TTK Healthcare completes Rs 250 crore pharma stake buyout to widen portfolio
Stock NewsTTKHLTCARE17 Jun 2026
TTK Healthcare Limited completed the buyout of the entire stake in a pharmaceutical firm in a deal valued at about Rs 250 crores. The transaction converted the target into a fully owned entity under TTK Healthcare, giving the company complete strategic and operational control over the acquired pharma business. By securing 100 percent ownership, TTK Healthcare eliminated minority interests and potential decision-making conflicts, enabling smoother integration of product pipelines, sales teams, and distribution networks.
The stated objective of the buyout was to boost TTK Healthcare's product range and expand its presence in the pharmaceutical market. The acquisition was expected to allow the company to broaden its therapeutic portfolio, potentially introduce new formulations, and enhance cross-selling opportunities across existing channels. Consolidation of the acquired firm's operations under TTK Healthcare's umbrella could support better utilisation of manufacturing capacities, procurement synergies, and a more efficient go-to-market strategy. Over time, this could improve revenue visibility and operating leverage, especially if the acquired products enjoy stronger margins or higher growth trajectories compared to the legacy portfolio.
From a strategic perspective, the Rs 250 crore outlay indicated a meaningful capital commitment towards strengthening the pharma vertical within TTK Healthcare's overall business mix. Depending on the funding structure, there could be implications for leverage and return on capital, but those details were not disclosed in the available information. The move signalled management's intent to scale up in the healthcare and pharma space, deepen market penetration, and compete more effectively in key therapeutic segments. Near-term financial impact would hinge on integration costs and execution, while the medium-term potential lay in higher market share and a more diversified product basket.
TTK Healthcare informs about AGM
Stock NewsTTKHLTCARE3 Jun 2026
NULL
TTK Healthcare Q4 EBITDA declines year-on-year with margin compression observed
ResultTTKHLTCARE30 May 2026
TTK Healthcare has reported its quarterly earnings, highlighting a year-on-year decline in operating performance for the fourth quarter. The company’s Q4 EBITDA stood at Rs 11.00 crores compared with Rs 12.00 crores in the same quarter last year, indicating a reduction in absolute operating profit on a yearly basis. This signals some pressure on operating performance versus the previous year, even though EBITDA remains in double digits. No data on revenue or profit after tax (PAT) is available in the provided context, so the impact on overall profitability beyond EBITDA cannot be ascertained.
EBITDA margin for Q4 came in at 5.06 percent compared with 6.31 percent on a year-on-year basis, reflecting margin compression. The decline in margin suggests that costs have risen faster than operating income or that the company has faced pricing or mix-related pressures during the quarter. Without revenue details, it is not possible to quantify the exact change in operating leverage, but the lower margin clearly indicates reduced efficiency or higher input or operating costs relative to the same period last year.
The data provided does not include quarter-on-quarter comparisons, street expectations, or management commentary, so any assessment of performance versus consensus or future outlook would be speculative and is therefore not included. There is also no information on market reaction or stock price movement for TTK Healthcare in response to these results. Overall, based solely on the available figures, the company has faced a modest decline in EBITDA and a more notable contraction in EBITDA margin on a year-on-year basis for Q4.
TTK Healthcare Q4 profit and revenue rise strongly on yearly basis
ResultTTKHLTCARE30 May 2026
TTK Healthcare reported a healthy set of numbers for the fourth quarter, with both revenue and profitability improving on a year-on-year basis. The company’s Q4 standalone net profit came in at Rs 21.80 crores, compared with Rs 16.10 crores in the same quarter last year, indicating a strong growth in bottom line performance. On the top line, Q4 revenue rose to Rs 220.00 crores from Rs 190.00 crores a year ago, reflecting a solid increase in sales. The simultaneous expansion in revenue and net profit suggests an improvement in operating leverage and overall business momentum during the quarter.
The sharp year-on-year rise in net profit, outpacing revenue growth, implies that TTK Healthcare may have benefited from better cost management, improved product mix, or higher operating efficiency, although detailed margin data is not provided in the context. The numbers indicate a positive earnings trajectory for the company on an annual comparison for Q4. However, the context does not provide quarter-on-quarter figures, EBITDA, operating margin, net margin details, or any street consensus/analyst expectations, so an assessment relative to market expectations cannot be made from the available information. In addition, no management commentary, segmental performance breakdown, or guidance has been provided in the given text, limiting forward-looking interpretation.
No information on the immediate stock price reaction, F&O activity, or flows is mentioned, so the market’s real-time response to these results cannot be inferred from the context alone. Overall, based purely on the disclosed Q4 revenue and net profit trajectory, the results represent a year-on-year improvement in financial performance for TTK Healthcare.
TTK Healthcare declares Rs 10 per share dividend after corporate results review
ResultTTKHLTCARE30 May 2026
TTK Healthcare has announced a corporate action in the form of a dividend recommendation of Rs 10 per equity share. This decision reflects the company’s board-approved payout proposal to shareholders based on its latest reviewed financial performance and internal capital allocation considerations. The announcement falls under the broader earnings and corporate results framework, indicating that the board has evaluated recent financials and cash flows before recommending this shareholder return. However, the specific revenue, EBITDA, and PAT figures, as well as year-on-year or quarter-on-quarter growth metrics, have not been disclosed in the provided context. Similarly, details on operating and net margin trends, as well as comparisons with street expectations or consensus estimates, are not available in the current information set.
Given the lack of explicit financial metrics, it is not possible to quantify the payout ratio, dividend yield, or to comment on whether the dividend represents an increase, decrease, or maintenance of prior years’ distribution levels. No management commentary, forward guidance, or qualitative assessment of business segments and demand outlook has been provided in the text. The context also does not specify the record date, ex-dividend date, or payment date for the dividend, nor does it mention any special or one-off nature of this distribution. There is no information on the immediate market reaction or stock price movement following the announcement, and no indication of how this dividend aligns with the company’s historical dividend policy or capital expenditure plans. In the absence of these details, the key confirmed takeaway is the board’s recommendation of a dividend of Rs 10 per equity share for TTK Healthcare as part of its latest corporate result communication.
TTK Healthcare reports Profit after tax of 21.76 Crores, in the March 2026 quarter
ResultTTKHLTCARE30 May 2026
NULL
TTK Healthcare informs about closure of trading window
Stock NewsTTKHLTCARE24 Mar 2026
NULL
TTK Healthcare - Quaterly Results
ResultTTKHLTCARE22 Jan 2026
NULL
TTK Healthcare Q3 Revenue at Rs 209 Crores, Up from Rs 205 Crores YoY.
ResultTTKHLTCARE22 Jan 2026
TTK Healthcare reported Q3 revenue of Rs 209.00 crores, marking an increase from Rs 205.00 crores in the year-ago quarter. This represents a modest YoY growth in top-line performance for the equity-listed company on NSE/BSE.
Additional quarterly data from recent filings indicate Sep '25 revenue at Rs 222.58 crores, down 8.92% QoQ from Rs 244.37 crores in Jun '25, with EBITDA rising to Rs 24.35 crores (up 18.15% QoQ) and net profit at Rs 20.39 crores (up 56.85% QoQ from Rs 13 crores). Alternative sources note Q4 2024-2025 revenue at Rs 209.05 crores, up 6.06% YoY from Rs 197.11 crores, though net profit declined 11.6% YoY to Rs 16.15 crores with net profit margin at 7.73%.
No specific details on EBITDA, PAT, or margin trends for the exact Q3 period in the primary context; focus remains on verifiable revenue uptick. Market data shows stock trading around Rs 989-1014 in recent sessions post-Jan 2026.
TTK Healthcare Q3 EBITDA Declines to Rs 7.20 Crores, Margin at 3.4% YoY.
ResultTTKHLTCARE22 Jan 2026
TTK Healthcare reported Q3 **EBITDA** of **Rs 7.20 crores**, down from **Rs 7.70 crores** year-over-year (YoY), with **EBITDA margin** contracting to **3.4%** from **3.75%** YoY. This indicates softer operating performance in the quarter.
Context from recent quarterly results shows mixed trends: For Sep '25 (Q2 FY26), revenue stood at **Rs 222.58 crores** (down 8.92% QoQ from Rs 244.37 crores), **EBITDA** rose to **Rs 24.35 crores** (up 18.15% QoQ), and net profit increased to **Rs 20.39 crores** (up 56.85% QoQ). No specific revenue or PAT figures provided directly for the referenced Q3 in the core announcement. Street expectations or management guidance unavailable in context.
Stock has underperformed, down 24.6% over past year versus Indian Pharmaceuticals industry (-2.8%) and market (+4.0%). Recent trading shows volatility around Rs 1000 levels in Jan 2026.

